ID   MLKL_HUMAN              Reviewed;         471 AA.
AC   Q8NB16; A6NCE4; Q8N6V0;
DT   05-SEP-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   12-OCT-2022, entry version 169.
DE   RecName: Full=Mixed lineage kinase domain-like protein {ECO:0000305};
DE            Short=hMLKL {ECO:0000303|PubMed:12471243};
GN   Name=MLKL {ECO:0000303|PubMed:22265413, ECO:0000312|HGNC:HGNC:26617};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND NOMENCLATURE.
RX   PubMed=12471243; DOI=10.1126/science.1075762;
RA   Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.;
RT   "The protein kinase complement of the human genome.";
RL   Science 298:1912-1934(2002).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:BAC03728.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Chondrocyte {ECO:0000312|EMBL:BAC03728.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAH28141.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Leukocyte {ECO:0000312|EMBL:AAH28141.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-125, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   FUNCTION, INTERACTION WITH RIPK3, ACTIVITY REGULATION, PHOSPHORYLATION AT
RP   THR-357 AND SER-358, AND MUTAGENESIS OF CYS-86; THR-357 AND SER-358.
RX   PubMed=22265413; DOI=10.1016/j.cell.2011.11.031;
RA   Sun L., Wang H., Wang Z., He S., Chen S., Liao D., Wang L., Yan J., Liu W.,
RA   Lei X., Wang X.;
RT   "Mixed lineage kinase domain-like protein mediates necrosis signaling
RT   downstream of RIP3 kinase.";
RL   Cell 148:213-227(2012).
RN   [11]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH PGAM5; RIPK1 AND RIPK3.
RX   PubMed=22265414; DOI=10.1016/j.cell.2011.11.030;
RA   Wang Z., Jiang H., Chen S., Du F., Wang X.;
RT   "The mitochondrial phosphatase PGAM5 functions at the convergence point of
RT   multiple necrotic death pathways.";
RL   Cell 148:228-243(2012).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH RIPK3.
RX   PubMed=22421439; DOI=10.1073/pnas.1200012109;
RA   Zhao J., Jitkaew S., Cai Z., Choksi S., Li Q., Luo J., Liu Z.G.;
RT   "Mixed lineage kinase domain-like is a key receptor interacting protein 3
RT   downstream component of TNF-induced necrosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:5322-5327(2012).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND MUTAGENESIS OF LEU-58; ILE-76;
RP   LEU-162 AND LEU-165.
RX   PubMed=24316671; DOI=10.1038/ncb2883;
RA   Cai Z., Jitkaew S., Zhao J., Chiang H.C., Choksi S., Liu J., Ward Y.,
RA   Wu L.G., Liu Z.G.;
RT   "Plasma membrane translocation of trimerized MLKL protein is required for
RT   TNF-induced necroptosis.";
RL   Nat. Cell Biol. 16:55-65(2014).
RN   [14]
RP   INTERACTION WITH RIPK3.
RX   PubMed=29883609; DOI=10.1016/j.molcel.2018.05.016;
RA   Choi S.W., Park H.H., Kim S., Chung J.M., Noh H.J., Kim S.K., Song H.K.,
RA   Lee C.W., Morgan M.J., Kang H.C., Kim Y.S.;
RT   "PELI1 selectively targets kinase-active RIP3 for ubiquitylation-dependent
RT   proteasomal degradation.";
RL   Mol. Cell 70:920-935(2018).
RN   [15]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-358, SUBUNIT, REGION
RP   NBB, AND SUBCELLULAR LOCATION.
RX   PubMed=29883610; DOI=10.1016/j.molcel.2018.05.010;
RA   Dovey C.M., Diep J., Clarke B.P., Hale A.T., McNamara D.E., Guo H.,
RA   Brown N.W. Jr., Cao J.Y., Grace C.R., Gough P.J., Bertin J., Dixon S.J.,
RA   Fiedler D., Mocarski E.S., Kaiser W.J., Moldoveanu T., York J.D.,
RA   Carette J.E.;
RT   "MLKL requires the inositol phosphate code to execute necroptosis.";
RL   Mol. Cell 70:936-948(2018).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 189-471, ATP-BINDING, AND
RP   MUTAGENESIS OF LYS-230; LYS-331 AND GLU-351.
RX   PubMed=24219132; DOI=10.1042/bj20131270;
RA   Murphy J.M., Lucet I.S., Hildebrand J.M., Tanzer M.C., Young S.N.,
RA   Sharma P., Lessene G., Alexander W.S., Babon J.J., Silke J., Czabotar P.E.;
RT   "Insights into the evolution of divergent nucleotide-binding mechanisms
RT   among pseudokinases revealed by crystal structures of human and mouse
RT   MLKL.";
RL   Biochem. J. 457:369-377(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 179-471.
RX   PubMed=24095729; DOI=10.1016/j.celrep.2013.08.044;
RA   Xie T., Peng W., Yan C., Wu J., Gong X., Shi Y.;
RT   "Structural insights into RIP3-mediated necroptotic signaling.";
RL   Cell Rep. 5:70-78(2013).
RN   [18]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-52; GLU-100; PRO-132; GLN-146; LEU-169;
RP   PRO-291; MET-364; ILE-398 AND HIS-421.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Pseudokinase that plays a key role in TNF-induced
CC       necroptosis, a programmed cell death process (PubMed:22265413,
CC       PubMed:22265414, PubMed:22421439, PubMed:24316671). Does not have
CC       protein kinase activity (PubMed:22265413, PubMed:22265414,
CC       PubMed:22421439, PubMed:24316671). Activated following phosphorylation
CC       by RIPK3, leading to homotrimerization, localization to the plasma
CC       membrane and execution of programmed necrosis characterized by calcium
CC       influx and plasma membrane damage (PubMed:22265413, PubMed:22265414,
CC       PubMed:22421439, PubMed:24316671). In addition to TNF-induced
CC       necroptosis, necroptosis can also take place in the nucleus in response
CC       to orthomyxoviruses infection: following activation by ZBP1, MLKL is
CC       phosphorylated by RIPK3 in the nucleus, triggering disruption of the
CC       nuclear envelope and leakage of cellular DNA into the cytosol.following
CC       ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear
CC       RIPK3 catalyzes phosphorylation and activation of MLKL, promoting
CC       disruption of the nuclear envelope and leakage of cellular DNA into the
CC       cytosol (By similarity). Binds to highly phosphorylated inositol
CC       phosphates such as inositolhexakisphosphate (InsP6) which is essential
CC       for its necroptotic function (PubMed:29883610).
CC       {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:22265413,
CC       ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439,
CC       ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}.
CC   -!- ACTIVITY REGULATION: Activated via binding to highly phosphorylated
CC       inositol phosphates such as inositolhexakisphosphate (InsP6) which
CC       mediates the release of an N-terminal auto-inhibitory region
CC       (PubMed:29883610). Activation requires not only RIPK3-dependent
CC       phosphorylation but also binding to highly phosphorylated inositol
CC       phosphates (PubMed:29883610). Inhibited by necrosulfonamide, a specific
CC       inhibitor of necroptosis that targets Cys-86 (PubMed:22265413).
CC       {ECO:0000269|PubMed:22265413, ECO:0000269|PubMed:29883610}.
CC   -!- SUBUNIT: Homooligomer (PubMed:29883610). Homotrimer; forms homotrimers
CC       on necroptosis induction (PubMed:24316671). Upon TNF-induced necrosis,
CC       forms in complex with PGAM5, RIPK1 and RIPK3 (PubMed:22265414). Within
CC       this complex, may play a role in the proper targeting of RIPK1-RIPK3 to
CC       its downstream effector PGAM5 (PubMed:22265414). Interacts with RIPK3;
CC       the interaction is direct and promotes its phosphorylation and
CC       subsequent activation (PubMed:22265413, PubMed:22421439,
CC       PubMed:29883609). {ECO:0000269|PubMed:22265413,
CC       ECO:0000269|PubMed:22265414, ECO:0000269|PubMed:22421439,
CC       ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883609,
CC       ECO:0000269|PubMed:29883610}.
CC   -!- INTERACTION:
CC       Q8NB16; Q9Y572: RIPK3; NbExp=10; IntAct=EBI-1055040, EBI-298250;
CC       Q8NB16-1; Q8NB16-1: MLKL; NbExp=2; IntAct=EBI-16084674, EBI-16084674;
CC       Q8NB16-2; P20618: PSMB1; NbExp=3; IntAct=EBI-19046912, EBI-372273;
CC       Q8NB16-2; P60903: S100A10; NbExp=3; IntAct=EBI-19046912, EBI-717048;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:24316671}. Cell
CC       membrane {ECO:0000269|PubMed:24316671, ECO:0000269|PubMed:29883610}.
CC       Nucleus {ECO:0000250|UniProtKB:Q9D2Y4}. Note=Localizes to the cytoplasm
CC       and translocates to the plasma membrane on necroptosis induction
CC       (PubMed:24316671). Localizes to the nucleus in response to
CC       orthomyxoviruses infection (By similarity).
CC       {ECO:0000250|UniProtKB:Q9D2Y4, ECO:0000269|PubMed:24316671}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000303|PubMed:12471243, ECO:0000303|PubMed:14702039};
CC         IsoId=Q8NB16-1; Sequence=Displayed;
CC       Name=2 {ECO:0000303|PubMed:15489334};
CC         IsoId=Q8NB16-2; Sequence=VSP_052133, VSP_052134;
CC   -!- DOMAIN: The protein kinase domain is catalytically inactive but
CC       contains an unusual pseudoactive site with an interaction between Lys-
CC       230 and Gln-356 residues (By similarity). Upon phosphorylation by
CC       RIPK3, undergoes an active conformation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9D2Y4}.
CC   -!- DOMAIN: The coiled coil region 2 is responsible for homotrimerization.
CC       {ECO:0000269|PubMed:24316671}.
CC   -!- PTM: Phosphorylation by RIPK3 induces a conformational switch that is
CC       required for necroptosis (PubMed:22265413). It also induces
CC       homotrimerization and localization to the plasma membrane
CC       (PubMed:22265413). {ECO:0000269|PubMed:22265413}.
CC   -!- MISCELLANEOUS: Interaction with RIPK3 is species specific: human MLKL
CC       only interacts with human RIPK3 and not mouse RIPK3.
CC       {ECO:0000305|PubMed:22265413}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK091708; BAC03728.1; -; mRNA.
DR   EMBL; AC109599; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC028141; AAH28141.1; -; mRNA.
DR   CCDS; CCDS32487.1; -. [Q8NB16-1]
DR   CCDS; CCDS45528.1; -. [Q8NB16-2]
DR   RefSeq; NP_001135969.1; NM_001142497.2. [Q8NB16-2]
DR   RefSeq; NP_689862.1; NM_152649.3. [Q8NB16-1]
DR   RefSeq; XP_005255891.1; XM_005255834.3. [Q8NB16-1]
DR   PDB; 2MSV; NMR; -; A=1-154.
DR   PDB; 4M67; X-ray; 1.90 A; A=179-471.
DR   PDB; 4MWI; X-ray; 1.70 A; A=183-471.
DR   PDB; 5KNJ; X-ray; 2.88 A; A/B=191-471.
DR   PDB; 5KO1; X-ray; 2.16 A; A=191-471.
DR   PDB; 6BWK; X-ray; 2.79 A; A=190-471.
DR   PDB; 6D74; NMR; -; A=1-156.
DR   PDB; 6LK5; X-ray; 2.50 A; A=1-471.
DR   PDB; 6LK6; X-ray; 2.41 A; A=179-471.
DR   PDB; 6O5Z; X-ray; 2.29 A; A/B=190-471.
DR   PDB; 6UX8; X-ray; 2.50 A; A=5-154.
DR   PDB; 6ZLE; NMR; -; A=2-154.
DR   PDB; 6ZPR; NMR; -; A=2-154.
DR   PDB; 6ZVO; X-ray; 1.37 A; A/B/C=2-150.
DR   PDB; 6ZZ1; X-ray; 1.64 A; A/B=2-150.
DR   PDB; 7JW7; X-ray; 2.63 A; A=190-471.
DR   PDB; 7JXU; X-ray; 2.44 A; A/B=190-471.
DR   PDB; 7MON; X-ray; 2.23 A; A=190-471.
DR   PDB; 7NM2; NMR; -; A=2-154.
DR   PDB; 7NM4; NMR; -; A=2-154.
DR   PDB; 7NM5; NMR; -; A=2-154.
DR   PDBsum; 2MSV; -.
DR   PDBsum; 4M67; -.
DR   PDBsum; 4MWI; -.
DR   PDBsum; 5KNJ; -.
DR   PDBsum; 5KO1; -.
DR   PDBsum; 6BWK; -.
DR   PDBsum; 6D74; -.
DR   PDBsum; 6LK5; -.
DR   PDBsum; 6LK6; -.
DR   PDBsum; 6O5Z; -.
DR   PDBsum; 6UX8; -.
DR   PDBsum; 6ZLE; -.
DR   PDBsum; 6ZPR; -.
DR   PDBsum; 6ZVO; -.
DR   PDBsum; 6ZZ1; -.
DR   PDBsum; 7JW7; -.
DR   PDBsum; 7JXU; -.
DR   PDBsum; 7MON; -.
DR   PDBsum; 7NM2; -.
DR   PDBsum; 7NM4; -.
DR   PDBsum; 7NM5; -.
DR   AlphaFoldDB; Q8NB16; -.
DR   BMRB; Q8NB16; -.
DR   SMR; Q8NB16; -.
DR   BioGRID; 128244; 32.
DR   DIP; DIP-41782N; -.
DR   IntAct; Q8NB16; 21.
DR   MINT; Q8NB16; -.
DR   STRING; 9606.ENSP00000308351; -.
DR   BindingDB; Q8NB16; -.
DR   ChEMBL; CHEMBL1938217; -.
DR   GuidetoPHARMACOLOGY; 2106; -.
DR   TCDB; 1.A.105.1.1; the mixed lineage kinase domain-like (mlkl) family.
DR   GlyGen; Q8NB16; 4 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; Q8NB16; -.
DR   PhosphoSitePlus; Q8NB16; -.
DR   BioMuta; MLKL; -.
DR   DMDM; 74762545; -.
DR   CPTAC; CPTAC-895; -.
DR   CPTAC; CPTAC-896; -.
DR   EPD; Q8NB16; -.
DR   jPOST; Q8NB16; -.
DR   MassIVE; Q8NB16; -.
DR   MaxQB; Q8NB16; -.
DR   PaxDb; Q8NB16; -.
DR   PeptideAtlas; Q8NB16; -.
DR   PRIDE; Q8NB16; -.
DR   ProteomicsDB; 72718; -. [Q8NB16-1]
DR   ProteomicsDB; 72719; -. [Q8NB16-2]
DR   Antibodypedia; 2097; 367 antibodies from 37 providers.
DR   DNASU; 197259; -.
DR   Ensembl; ENST00000306247.11; ENSP00000303118.7; ENSG00000168404.13. [Q8NB16-2]
DR   Ensembl; ENST00000308807.12; ENSP00000308351.7; ENSG00000168404.13. [Q8NB16-1]
DR   GeneID; 197259; -.
DR   KEGG; hsa:197259; -.
DR   MANE-Select; ENST00000308807.12; ENSP00000308351.7; NM_152649.4; NP_689862.1.
DR   UCSC; uc002fdb.3; human. [Q8NB16-1]
DR   CTD; 197259; -.
DR   DisGeNET; 197259; -.
DR   GeneCards; MLKL; -.
DR   HGNC; HGNC:26617; MLKL.
DR   HPA; ENSG00000168404; Low tissue specificity.
DR   MalaCards; MLKL; -.
DR   MIM; 615153; gene.
DR   neXtProt; NX_Q8NB16; -.
DR   OpenTargets; ENSG00000168404; -.
DR   PharmGKB; PA142671349; -.
DR   VEuPathDB; HostDB:ENSG00000168404; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00390000016453; -.
DR   HOGENOM; CLU_044216_0_0_1; -.
DR   InParanoid; Q8NB16; -.
DR   OMA; ESKVDWM; -.
DR   OrthoDB; 1388260at2759; -.
DR   PhylomeDB; Q8NB16; -.
DR   TreeFam; TF328453; -.
DR   PathwayCommons; Q8NB16; -.
DR   Reactome; R-HSA-3295583; TRP channels.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-9686347; Microbial modulation of RIPK1-mediated regulated necrosis.
DR   SignaLink; Q8NB16; -.
DR   SIGNOR; Q8NB16; -.
DR   BioGRID-ORCS; 197259; 15 hits in 1114 CRISPR screens.
DR   ChiTaRS; MLKL; human.
DR   GenomeRNAi; 197259; -.
DR   Pharos; Q8NB16; Tchem.
DR   PRO; PR:Q8NB16; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q8NB16; protein.
DR   Bgee; ENSG00000168404; Expressed in granulocyte and 164 other tissues.
DR   ExpressionAtlas; Q8NB16; baseline and differential.
DR   Genevisible; Q8NB16; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0051607; P:defense response to virus; ISS:UniProtKB.
DR   GO; GO:0097528; P:execution phase of necroptosis; ISS:UniProtKB.
DR   GO; GO:0070266; P:necroptotic process; IMP:UniProtKB.
DR   GO; GO:0097527; P:necroptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070207; P:protein homotrimerization; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   Gene3D; 1.20.930.20; -; 1.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Coiled coil; Cytoplasm; Membrane; Necrosis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..471
FT                   /note="Mixed lineage kinase domain-like protein"
FT                   /id="PRO_0000248239"
FT   DOMAIN          194..469
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..149
FT                   /note="N-terminal bundle and brace (NBB); mediates INSP6
FT                   binding"
FT                   /evidence="ECO:0000269|PubMed:29883610"
FT   COILED          55..84
FT                   /evidence="ECO:0000255"
FT   COILED          139..180
FT                   /evidence="ECO:0000255"
FT   BINDING         209..217
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         230
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   SITE            86
FT                   /note="Target of necrosulfonamide inhibitor"
FT                   /evidence="ECO:0000269|PubMed:22265413"
FT   MOD_RES         125
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976"
FT   MOD_RES         357
FT                   /note="Phosphothreonine; by RIPK3"
FT                   /evidence="ECO:0000269|PubMed:22265413"
FT   MOD_RES         358
FT                   /note="Phosphoserine; by RIPK3"
FT                   /evidence="ECO:0000269|PubMed:22265413,
FT                   ECO:0000269|PubMed:29883610"
FT   MOD_RES         360
FT                   /note="Phosphoserine; by RIPK3"
FT                   /evidence="ECO:0000250|UniProtKB:Q9D2Y4"
FT   VAR_SEQ         179..205
FT                   /note="YLPPKCMQEIPQEQIKEIKKEQLSGSP -> SLESSSGKSPLEISRFKVKNV
FT                   KTGSAS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_052133"
FT   VAR_SEQ         206..413
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_052134"
FT   VARIANT         52
FT                   /note="S -> T (in dbSNP:rs34251827)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041350"
FT   VARIANT         100
FT                   /note="D -> E (in dbSNP:rs33987771)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041351"
FT   VARIANT         132
FT                   /note="S -> P (in dbSNP:rs35589326)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041352"
FT   VARIANT         146
FT                   /note="R -> Q (in dbSNP:rs34515646)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041353"
FT   VARIANT         169
FT                   /note="M -> L (in dbSNP:rs55929310)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041354"
FT   VARIANT         291
FT                   /note="L -> P (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1313508921)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041355"
FT   VARIANT         364
FT                   /note="T -> M (in dbSNP:rs34389205)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041356"
FT   VARIANT         398
FT                   /note="F -> I (in a gastric adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041357"
FT   VARIANT         421
FT                   /note="R -> H (in dbSNP:rs55987292)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041358"
FT   MUTAGEN         58
FT                   /note="L->G: Does not affect formation of homotrimers,
FT                   while translocation to the plasma membrane on necroptosis
FT                   induction is impaired; when associated with G-76."
FT                   /evidence="ECO:0000269|PubMed:24316671"
FT   MUTAGEN         76
FT                   /note="I->G: Does not affect formation of homotrimers,
FT                   while translocation to the plasma membrane on necroptosis
FT                   induction is impaired; when associated with G-58."
FT                   /evidence="ECO:0000269|PubMed:24316671"
FT   MUTAGEN         86
FT                   /note="C->S: Abolishes binding to necrosulfonamide
FT                   inhibitor."
FT                   /evidence="ECO:0000269|PubMed:22265413"
FT   MUTAGEN         162
FT                   /note="L->G: Impairs formation of homotrimers and
FT                   translocation to the plasma membrane on necroptosis
FT                   induction; when associated with G-165."
FT                   /evidence="ECO:0000269|PubMed:24316671"
FT   MUTAGEN         165
FT                   /note="L->G: Impairs formation of homotrimers and
FT                   translocation to the plasma membrane on necroptosis
FT                   induction; when associated with G-162."
FT                   /evidence="ECO:0000269|PubMed:24316671"
FT   MUTAGEN         230
FT                   /note="K->M: Abolishes ATP-binding."
FT                   /evidence="ECO:0000269|PubMed:24219132"
FT   MUTAGEN         331
FT                   /note="K->N: Impairs ATP-binding."
FT                   /evidence="ECO:0000269|PubMed:24219132"
FT   MUTAGEN         351
FT                   /note="E->K: Binds ATP with an enhanced affinity."
FT                   /evidence="ECO:0000269|PubMed:24219132"
FT   MUTAGEN         357..358
FT                   /note="TS->ED: Mimics phosphorylation state; acts as a
FT                   dominant-negative mutant that impairs necroptosis."
FT   MUTAGEN         357
FT                   /note="T->A: No effect. Abolishes ability to mediate
FT                   necroptosis; when associated with A-358."
FT                   /evidence="ECO:0000269|PubMed:22265413"
FT   MUTAGEN         358
FT                   /note="S->A: No effect. Abolishes ability to mediate
FT                   necroptosis; when associated with A-357."
FT                   /evidence="ECO:0000269|PubMed:22265413"
FT   HELIX           2..20
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   STRAND          22..24
FT                   /evidence="ECO:0007829|PDB:6ZZ1"
FT   HELIX           25..46
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   HELIX           56..79
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   HELIX           82..90
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   STRAND          93..96
FT                   /evidence="ECO:0007829|PDB:2MSV"
FT   HELIX           99..120
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   TURN            128..132
FT                   /evidence="ECO:0007829|PDB:2MSV"
FT   HELIX           133..148
FT                   /evidence="ECO:0007829|PDB:6ZVO"
FT   HELIX           198..201
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          202..204
FT                   /evidence="ECO:0007829|PDB:6O5Z"
FT   STRAND          207..211
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          213..222
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          225..232
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           240..256
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          265..271
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          274..276
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          278..284
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           291..297
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           303..322
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           334..336
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          337..339
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          345..347
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          349..352
FT                   /evidence="ECO:0007829|PDB:7MON"
FT   HELIX           353..359
FT                   /evidence="ECO:0007829|PDB:7MON"
FT   TURN            360..362
FT                   /evidence="ECO:0007829|PDB:7JXU"
FT   HELIX           373..376
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           379..383
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           391..407
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   TURN            411..414
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           417..425
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   STRAND          435..437
FT                   /evidence="ECO:0007829|PDB:6O5Z"
FT   HELIX           439..448
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           453..455
FT                   /evidence="ECO:0007829|PDB:4MWI"
FT   HELIX           459..467
FT                   /evidence="ECO:0007829|PDB:4MWI"
SQ   SEQUENCE   471 AA;  54479 MW;  005E7F7AB6D20649 CRC64;
     MENLKHIITL GQVIHKRCEE MKYCKKQCRR LGHRVLGLIK PLEMLQDQGK RSVPSEKLTT
     AMNRFKAALE EANGEIEKFS NRSNICRFLT ASQDKILFKD VNRKLSDVWK ELSLLLQVEQ
     RMPVSPISQG ASWAQEDQQD ADEDRRAFQM LRRDNEKIEA SLRRLEINMK EIKETLRQYL
     PPKCMQEIPQ EQIKEIKKEQ LSGSPWILLR ENEVSTLYKG EYHRAPVAIK VFKKLQAGSI
     AIVRQTFNKE IKTMKKFESP NILRIFGICI DETVTPPQFS IVMEYCELGT LRELLDREKD
     LTLGKRMVLV LGAARGLYRL HHSEAPELHG KIRSSNFLVT QGYQVKLAGF ELRKTQTSMS
     LGTTREKTDR VKSTAYLSPQ ELEDVFYQYD VKSEIYSFGI VLWEIATGDI PFQGCNSEKI
     RKLVAVKRQQ EPLGEDCPSE LREIIDECRA HDPSVRPSVD EILKKLSTFS K
//
